Published in Cancer Weekly, May 18th, 2010
"In a previous microarray study, we found that VDR activation induces TMPRSS2 expression in LNCaP prostate cancer cells. Here we show that the natural VDR agonist 1 alpha,25-dihydroxyvitamin D-3 and its synthetic analog EB1089 increase expression of TMPRSS2: ERG...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.